Opinion

Video

Disease Progression Beyond Frontline KRAS G12C Inhibitors

Author(s):

Joshua K. Sabari, MDEdward B. Garon, MD, MS

Expert oncologists discuss patients who may progress to the second line setting with KRAS G12C mutations.

Related Videos
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
A panel of 3 experts on breast cancer
A panel of 3 experts on breast cancer
David R. Spigel, MD, chief scientific officer, Sarah Cannon Research Institute
Video 6 - "Reflex Testing for Patients with Suspected Lung Cancer"
Video 5 "Biomarker Testing in Early-Stage NSCLC"
Suresh Ramalingam, MD, and Chandler Park, MD
Related Content
Fabrice Barlesi, MD, PhD
June 10th 2024

Adjuvant Alectinib Approved in Europe for ALK+ Early-Stage NSCLC

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Minesh Mehta, MD
June 4th 2024

TTFields Plus BSC Prolongs Time to Intracranial Progression in NSCLC Brain Metastases

Hari B. Keshava, MD
October 23rd 2023

Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection

David Planchard, MD, PhD
June 4th 2024

Osimertinib Plus Chemotherapy Moves One Step Closer to EU Approval in EGFR+ Advanced NSCLC

Tina Cascone, MD, PhD, of The University of Texas MD Anderson Cancer Center
June 3rd 2024

Perioperative Nivolumab Regimen Improves EFS, Resection Rates in Stage III N2/non-N2 NSCLC